Alpha-GPC (L-Alpha-Glycerylphosphorylcholine)
NootropicLast reviewed on July 10, 2025 by SupStaq
Not medical advice. This content is general, evidence-based information and is not a substitute for professional medical advice, diagnosis, or treatment.
The small divergence of -4 points reflects broad agreement between clinical evidence [s5, s7] and user experiences [c1, c2]. The community score is slightly higher, as users consistently report acute focus and memory effects, while the medical literature is tempered by the stroke risk signal [s10, s11] and small study populations in healthy individuals.
Unlock full information
Dosages, side effects, studies and more, free after registration.
Register for freeRating Scales
TL;DR
Alpha-GPC is the best-evidenced choline source for cognitive purposes: multiple RCTs and a 2023 meta-analysis show consistent improvements in Alzheimer's/dementia (MMSE MD +3.50), while evidence in healthy adults is stronger than most nootropics but remains smaller-scale and less consistent. The key safety concern is a cohort study (n=~82,000) suggesting elevated stroke risk with chronic use — not causally proven, but sufficient reason to avoid daily doses above 600 mg in those with cardiovascular risk factors. For healthy adults, Alpha-GPC remains one of the few nootropics with genuine efficacy data; cycling or as-needed use is preferable to daily supplementation.
Description
Alpha-GPC is a highly bioavailable choline compound that crosses the blood-brain barrier, promotes acetylcholine synthesis, and supports cognitive function and muscular performance [s1, s2].
Alpha-GPC (L-Alpha-glycerylphosphorylcholine) is a naturally occurring phospholipid metabolite found in the brain, human breast milk, and in small amounts in various foods such as organ meats and wheat [s1]. It is a degradation product of phosphatidylcholine and represents a highly bioavailable choline source that crosses the blood-brain barrier more efficiently than other choline forms (e.g., choline bitartrate) [s1, s2]. Following oral ingestion, Alpha-GPC is absorbed in the intestine and rapidly cleaved into choline and glycerophosphate. The released choline serves as a direct precursor for synthesis of the neurotransmitter acetylcholine and for incorporation into phospholipids of neuronal cell membranes [s1, s2]. Studies in rats demonstrate that Alpha-GPC is incorporated into brain phospholipids within 24 hours of ingestion [s1]. Clinically, Alpha-GPC has been investigated primarily in neurology for cognitive impairment, Alzheimer's dementia, and post-stroke recovery [s4, s5, s6]. A 2023 meta-analysis demonstrated significant improvements in MMSE scores versus placebo or other medications (MD 3.50; 95% CI: 0.36 to 6.63) [s5]. In the sports and performance domain, an acute GH increase (44-fold vs. baseline) following a single dose of 600 mg has been documented [s7]. A cohort study published in 2022 indicated an elevated stroke risk in older patients with cardiovascular risk factors, influencing the ongoing safety discussion [s10]. For healthy adults, typical dosages range from 300 to 600 mg daily, divided into 1–3 doses. Alpha-GPC is commercially available as a dietary supplement in Germany; the regulatory situation varies depending on manufacturing method and country [s13, s14, s15].
Legal Status (DE)
In Germany and Austria, Alpha-GPC is freely available as a dietary supplement, provided it is derived from natural sources (e.g., soy lecithin) [s13]. Synthetically produced Alpha-GPC is classified in Switzerland by the FSVO as a novel food (Novel Food) under Art. 15 Para. 1 of the Food Act and requires authorization [s14]. The EFSA published a novel food opinion on L-alpha-GPC from soy phospholipids in 2026 [s15]. As a prescription medicinal product (choline alfoscerate), it is used in several EU countries (e.g., Italy) for the treatment of cognitive disorders.
Mechanism of Action
Alpha-GPC acts primarily through three interconnected mechanisms [s1, s2]: 1. **Acetylcholine synthesis**: Following absorption and cleavage, Alpha-GPC supplies choline, which is converted via choline acetyltransferase (ChAT) with acetyl-CoA to acetylcholine (ACh). ACh is a central neurotransmitter for memory, learning, attention, and neuromuscular transmission [s1, s2]. 2. **Phospholipid synthesis and membrane integrity**: Alpha-GPC is directly incorporated into phosphatidylcholine and other membrane phospholipids, improving the fluidity and integrity of neuronal membranes. This mechanism is particularly relevant in degenerative diseases such as Alzheimer's, in which membrane phospholipids are degraded [s1, s4]. 3. **Growth hormone secretion**: Alpha-GPC stimulates the release of growth hormone (GH) from the pituitary gland, presumably via cholinergic stimulation of hypothalamic GHRH neurons. In an RCT, peak GH levels increased 44-fold from baseline following 600 mg Alpha-GPC [s7]. 4. **TMAO pathway (potentially adverse)**: Choline can be converted by gut bacteria to trimethylamine (TMA) and further oxidized hepatically to trimethylamine N-oxide (TMAO). Elevated TMAO levels have been associated with atherogenic processes and increased stroke risk [s10, s11].
Dosing
Kognitive Leistung / Fokus (gesunde Erwachsene)
- Dose
- 300–600 mg Alpha-GPC (equivalent to ~120–240 mg elemental choline)
- Frequency
- 1–2× täglich
- Route
- oral
- Duration
- fortlaufend oder bedarfsweise
- Timing
- Morning and/or midday; avoid in the evening due to possible sleep disturbance
- With food
- optional
Alzheimer-Demenz / kognitive Beeinträchtigung (klinisch)
- Dose
- 400 mg 3× daily (1200 mg/day)
- Frequency
- 3× täglich
- Route
- oral
- Duration
- 3–6 Monate (unter ärztlicher Aufsicht)
- Timing
- With meals
- With food
- empfohlen
Sportliche Leistung / Wachstumshormon-Stimulation
- Dose
- 600 mg Alpha-GPC
- Frequency
- 1× täglich, 60 Minuten vor dem Training
- Route
- oral
- Duration
- Akute Anwendung oder bis 6 Wochen
- Timing
- 60 minutes before resistance training
- With food
- optional
There is no officially established Tolerable Upper Intake Level (UL) for Alpha-GPC as a dietary supplement. In clinical studies, doses of up to 1200 mg/day have been used over 6 months without serious adverse effects [s4, s5]. Higher doses (>1200 mg/day) have not been sufficiently investigated. Given the potential stroke risk signal with chronic use, sustained doses >600 mg/day are discouraged in older individuals with cardiovascular risk factors [s10].
Alpha-GPC powder is hygroscopic and should be stored in an airtight container. Commercial products often contain 50% or 85% pure Alpha-GPC, so label dosages must be adjusted accordingly [s1].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Schlaganfallrisiko erhöht (Beobachtungsdaten) | gelegentlich | leicht |
Contraindications
A cohort study associates chronic alpha-GPC intake with increased stroke risk; TMAO-mediated mechanism is potentially pro-inflammatory and atherogenic [s10, s11]. Benefit-risk assessment required.
Increased choline intake exacerbates TMA accumulation in the absence of the FMO3 enzyme, leading to severe body odor burden [s11].
Soy-based Alpha-GPC may trigger allergic reactions in individuals with soy allergy [s15].
Insufficient safety data for Alpha-GPC supplementation during pregnancy and lactation. Choline occurs naturally in breast milk; targeted supplementation has not been adequately studied [s1].
Interactions
Synergistic
Racetams increase cerebral acetylcholine turnover; Alpha-GPC provides the choline precursor and prevents cholinergic depletion. Classic combination in the nootropics community [c2, c3].
In clinical studies, Alpha-GPC has been investigated as an adjunct to donepezil in Alzheimer's disease; additive cholinergic effect possible [s4].
The combination links the rapid acetylcholine boost from Alpha-GPC with the long-term membrane lipid synthesis provided by citicoline. Total choline intake should be carefully monitored to avoid oversupply.
Huperzine A inhibits acetylcholine degradation via acetylcholinesterase inhibition, while Alpha-GPC increases acetylcholine production. This combination can synergistically enhance cholinergic activity and demonstrates augmented neuroprotective effects in studies.
Users report improved memory performance, mental drive, and mood resilience with this combination. ALCAR supports mitochondrial energy metabolism in the brain, while Alpha-GPC promotes acetylcholine production.
The combination addresses both the structural (neuronal growth via Bacopa) and chemical (acetylcholine supply via Alpha-GPC) aspects of memory formation. This may provide more comprehensive cognitive support than either substance alone.
Lion's Mane promotes neurogenesis via NGF stimulation, while Alpha-GPC optimizes neurotransmitter supply. This combination is described in the nootropics community as particularly effective for long-term cognitive support.
Caution
Opposing effects: Alpha-GPC enhances cholinergic activity, anticholinergics inhibit it. Concurrent use mutually negates effects [s1].
Additive cholinergic effect may cause cholinergic overstimulation (bradycardia, hypersalivation, GI cramps) [s4, s5].
Given the potential stroke risk signal associated with Alpha-GPC, caution is warranted with concomitant use of anticoagulants; interaction not directly established, but clinically relevant [s10].
Although the combination may act synergistically, the additive cholinergic effect increases the risk of adverse effects such as nausea, bradycardia, hypersalivation, and gastrointestinal cramps. Careful dosing is absolutely required.
Concurrent intake of both choline sources can lead to excessive choline intake. Excess choline can cause nausea, headache, dizziness, and a fishy body odor.
Studies
Tier B: Moderate Evidence
Effect Size: Total stroke aHR 1.46 (95% CI 1.43–1.48); ischemic stroke aHR 1.36 (95% CI 1.33–1.39); hemorrhagic stroke aHR 1.36 (95% CI 1.28–1.44); dose-dependent association confirmed
Tier C: Low Evidence
Effect Size: Significant promotion of atherosclerosis; elevated TMAO levels; reduced Akkermansia and Lactobacillus
Community Evidence
Top reported benefits
- Enhanced mental focus and clearer thinking
- Improved memory performance and learning ability
- Increased physical energy and exercise performance
- Good adjunct to racetams (prevents headaches)
- Noticeable effect after a single dose
Top reported issues
- Headaches with overdose (>600 mg) or excessive frequency of use
- Depressive mood or emotional blunting in sensitive users
- Sleep disturbances when taken in the evening
- Dependency sensation / headaches upon discontinuation with daily use
Community discussion has been strongly shaped since 2022 by the TMAO-stroke controversy [c3]. Many experienced users have reduced daily intake and now use Alpha-GPC only on an as-needed basis. The dependency potential due to withdrawal headaches with long-term daily use is increasingly being discussed [c1, c2].
Scientific Sources
- Alpha-glycerylphosphorylcholine (Alpha-GPC): Examine.com Research Summary
Examine.com Editorial Team (2024). Examine.comDLink - The Nutritional Supplement L-Alpha Glycerylphosphorylcholine Promotes Atherosclerosis
Lam V, Su J, Koprowski S, et al. (2021). PMC / Circulation ResearchCLink - Association between L-α glycerylphosphorylcholine use and delayed dementia conversion / stroke risk: A nationwide longitudinal study in South Korea
Kim J, Park S, Lee H, et al. (2025). PMC / Frontiers in Neurology or equivalentBLink - Comparison of the effects of choline alphoscerate and citicoline in patients with dementia disorders: a systematic review and meta-analysis
Frontiers in Neurology Editorial, et al. (2025). Frontiers in NeurologyADOI - Alpha-GPC (Cholinalfoscerat) – DocCheck Flexikon
DocCheck Medical Services GmbH (2023). DocCheck FlexikonBLink - Einstufung von synthetischem L-Alpha-Glycerylphosphorylcholin (Alpha-GPC) als neuartiges Lebensmittel
Bundesamt für Lebensmittelsicherheit und Veterinärwesen (BLV) (2023). BLV / Schweizer LebensmittelrechtALink - Safety of L-alpha-glycerylphosphorylcholine (L-alpha-GPC) from soya phospholipids (lecithin) as a novel food pursuant to Regulation (EU) 2015/2283
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) (2026). EFSA JournalADOI - Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years
Lee G, Choi S, Chang J, Choi D, Son JS, Kim K, Kim SM, Jeong S, Park SM (2021). JAMA Network OpenCDOI - L-α-Glycerylphosphorylcholin – Wikipedia (Deutsch)
Wikipedia-Autoren (2024). WikipediaDLink - Glycerophosphorylcholine – Wikipedia (English)
Wikipedia contributors (2024). WikipediaDLink - Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial
De Jesus Moreno Moreno M (2003). Clinical TherapeuticsAPMID:12637119DOI - Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis
Sagaro GG, Traini E, Amenta F (2023). Journal of Alzheimer's DiseaseAPMID:36911935DOI - A Single-Blind, Randomized, Placebo-Controlled Human Study (Alpha-GPC cognitive function)
Parnetti L, Mignini F, Tomassoni D, et al. (2007). PMC / Neurological SciencesALink - Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to, and peak force production during, resistance exercise
Ziegenfuss TN, Landis J, Hofheins JE (2008). Journal of the International Society of Sports NutritionADOI - Acute Alpha-Glycerylphosphorylcholine Supplementation on Cognitive Performance and Power Output in Resistance-Trained Men (crossover RCT)
Marcus L, Soileau J, Judge LW, et al. (2017). PubMed / JISSNAPMID:39683633 - The effects of alpha-glycerylphosphorylcholine, caffeine or placebo on markers of mood, cognitive function, power, speed, and agility (6-week RCT)
Bellar D, LeBlanc NR, Campbell B (2015). Journal of the International Society of Sports NutritionAPMID:26582461DOI
Community Sources
Storage
Unopened
Store in a dry, cool place (15–25°C), protected from direct sunlight and moisture.
Opened
Alpha-GPC powder is strongly hygroscopic: seal the container immediately after use; silica gel packets are recommended. Capsules are less susceptible.
Notes
If stored improperly, Alpha-GPC powder can clump and lose potency. Optimal storage temperature below 25°C; refrigeration is not necessary but is possible provided moisture condensation is avoided.